With China taking steps to enact or propose amendments to more than 60 intellectual property (IP)-related laws and regulations over the past few years, drug and device companies doing business in the country need to keep abreast of the changes. Despite China’s efforts, most of the participants in the Feb. 9 U.S. Patent and Trademark Office’s quarterly China IP webinar indicated in a pre-webinar survey that they have yet to see much of an improvement in China’s enforcement and regulation of IP rights.
Fox Chase Chemical Diversity Center Inc. has described novel bis-amide containing compounds reported to be useful for the treatment of fungal infections.
Japan's National Center for Global Health and Medicine (NCGM) has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).
Aphiotx Inc. has identified sulfamoyl benzene derivatives acting as pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of opioid withdrawal.
Sichuan Haisco Pharmaceutical Co. Ltd. has synthesized selective estrogen receptor degradation inducers (SERDs) reported to be useful for the treatment of cancer.
Denali Therapeutics Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of stroke, gout, multiple sclerosis, Alzheimer's disease, hypertension, silicosis, graft-versus-host disease and nonalcoholic steatohepatitis (NASH).
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has identified G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of multiple sclerosis, inflammatory bowel disease, fibrosis, neurodegenerative disease and arthritis.
Acea Therapeutics Inc. and Hangzhou Acea Biosciences Co. Ltd. have described heterocyclic compounds acting as tyrosine kinase inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged imidazole derivatives reported to be useful for the treatment of bacterial infections.
Eternygen UK Ltd. has disclosed 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives acting as sodium-coupled citrate transporter 5 (SLC13A5) inhibitors reported to be useful for the treatment of eating disorders, liver cancer, neurodegeneration, and liver and metabolic diseases.
RSS
